Artificial intelligence to help cancer treatment "AI liver cancer clinical decision support system" was released in Sichuan

Chengdu, November 10 (Wang Peng) Doctors input the disease data of liver cancer patients into the artificial intelligence system, and the system immediately gives the treatment plan after "calculation", as well as the patient's survival cycle, recurrence probability and recurrence cycle and other predicted values. The Ninth National Hepatobiliary and Pancreatic Disease Summit Forum was held in Chengdu, Sichuan on the 9th, and the reporter learned from the scene that the "AI Liver Cancer Clinical Decision Support System" released on the same day was like an authoritative liver cancer expert, which can realize the intelligent diagnosis and treatment of liver cancer.

In recent years, the research and development and application of artificial intelligence have become more and more extensive, and in the medical field, "artificial intelligence + tumor prevention" has attracted more and more attention. Liver cancer is commonly known as the "king of cancer", the number of new cases of liver cancer in China is more than 400,000 per year, accounting for 50% of the total number of liver cancers in the world, but the prognosis is poor, and the five-year survival rate after surgery is only about 30%.

Professor Yan Lunan, Department of Liver Surgery, West China Hospital of Sichuan University, introduced that China's liver cancer treatment methods include surgical resection, liver transplantation, local ablation, interventional therapy, radiotherapy, targeted therapy, immunobiological therapy, etc., and various treatment routes are cross-complex, although relevant treatment guidelines have been issued at home and abroad, but in the actual clinical decision-making, it still relies heavily on the clinical experience and judgment of the attending doctor. "Especially for primary hospitals and young doctors, the lack of treatment experience affects the most appropriate decisions they make, which in turn affects the prognosis of patients."

In this context, West China Hospital has jointly developed the "AI Liver Cancer Clinical Decision Support System" and the "AI Liver Transplant Clinical Decision Making System" by using a large number of liver cancer case data accumulated over the years and together with the medical library cloud to assist doctors in giving patients appropriate treatment.

"The hospital's data system precipitates a large number of case data, condensing the experience and wisdom of hospital doctors, if these resources can be rationally used to support and support the doctor's clinical decision-making, it has great value." Professor Zhang Qunhua, CEO of Medical Library Cloud, introduced that it is precisely because China is a big country with liver cancer and a huge database that it has inherent advantages in the field of medical artificial intelligence.

According to reports, the system is based on a large amount of medical data, the use of big data analysis and AI algorithms, from which to train and learn from the previous doctor's treatment experience, and then give the corresponding treatment suggestions, but also established a liver cancer treatment knowledge logical framework, according to the data entered by patients to automate treatment judgment.

Ultimately, the system can not only provide treatment options for liver cancer patients, as well as predictive values such as survival cycle, recurrence probability and recurrence cycle, but also provide patients with treatment plans, treatment medications, and disease development of similar patients.

Professor Wen Tianfu, director of the Department of Liver Surgery of West China Hospital, said that the "AI Liver Cancer Clinical Decision Support System" can provide evidence-based, personalized, multi-level, long-term, prioritized treatment plans and strategies, thereby helping liver cancer doctors or clinical teams make faster and more accurate treatment decisions. "After the grass-roots hospitals are connected to the system in the future, it is equivalent to introducing an expert with leading domestic technology in the field of liver cancer, which will benefit liver cancer patients and have a profound impact on the ability of commercial insurance development paths." (End)